financetom
Business
financetom
/
Business
/
Barclays slashes India's FY22 GDP forecast to 10% amid COVID-19 surge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Barclays slashes India's FY22 GDP forecast to 10% amid COVID-19 surge
May 3, 2021 9:25 AM

Barclays Securities has cut India’s GDP growth forecast for financial year 2021-22 to 10 percent year-on-year from 11 percent earlier due to the fast spreading second wave of COVID-19 pandemic, reported Business Today.

Share Market Live

NSE

Barclays researcher Rahul Bajoria and Shreya Sodhani said the economic impact of the second COVID-19 pandemic could be "much higher" in the research note titled ‘India: Tracking COVID-19 and Vaccines,’ the report added.

The researchers are of the view that if Indian states continue with COVID-19 related restrictions till August 2021, it could result in a downside of 120 basis points on annual real GDP growth, dragging FY2021-22 growth to 8.8 percent YoY.

The researchers also predicted that the economic losses could be much higher due to the slow pace of vaccination and lockdowns in various states.

The Barclays note said that there is growing uncertainty around the number of cases and fatalities because of the ongoing second COVID-19 wave in India. It also added, ‘slowing vaccinations are hurting India's recovery prospects.’

India has reported over 3.6 lakh new COVID-19 cases on May 3 and 3,417 deaths in the last 24 hours, according to the health ministry data.

India has started a mass immunisation programme with an aim to cover everyone above the age of 18 but many states have not been able to begin vaccination due to rising supply constraints and logistical challenges.

With India not going for a nationwide lockdown so far, Barclays felt that the economic costs of the current surge in novel COVID-19 cases are much lower than during last year's national lockdown, but the bill is rising, the report said.

(Edited by : Shoma)

First Published:May 3, 2021 6:25 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia's Woodside inks LNG supply deal with Turkey's BOTAS
Australia's Woodside inks LNG supply deal with Turkey's BOTAS
Sep 24, 2025
(Reuters) -Australia's Woodside Energy said on Wednesday it has clinched an agreement to supply about 5.8 billion cubic metres of liquefied natural gas, to Turkish state-owned petroleum company BOTAS. Australia's biggest natural gas producer has agreed to supply for a period of nine years starting from 2030, primarily from its Louisiana LNG project, according to a company statement. The deal comes at...
Applied Materials to Collaborate With GlobalFoundries on Singapore Waveguide Fabrication Facility
Applied Materials to Collaborate With GlobalFoundries on Singapore Waveguide Fabrication Facility
Sep 24, 2025
04:16 AM EDT, 09/24/2025 (MT Newswires) -- Applied Materials ( AMAT ) said late Tuesday it will work with GlobalFoundries ( GFS ) to set up a waveguide fabrication facility at GlobalFoundries' ( GFS ) Singapore project to support the growing use of photonics in artificial intelligence technologies. Applied Materials ( AMAT ) will develop waveguide components, with GlobalFoundries (...
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Sep 24, 2025
By Muvija M LONDON (Reuters) -Eli Lilly ( LLY ) Chief Executive Dave Ricks said Britain was probably the worst country in Europe for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers. The remarks are part of a broader backlash from pharmaceutical giants, including Merck ( MRK )...
GE Healthcare, Lantheus Strike Licensing Deal for Prostate Cancer Imaging Agent in Japan
GE Healthcare, Lantheus Strike Licensing Deal for Prostate Cancer Imaging Agent in Japan
Sep 24, 2025
04:06 AM EDT, 09/24/2025 (MT Newswires) -- GE Healthcare Technologies ( GEHC ) has agreed to develop, manufacture and commercialize Lantheus' ( LNTH ) piflufolastat F18 for prostate cancer diagnostics and companion diagnostic use in Japan, the companies said Wednesday. Under the exclusive licensing agreement, GE Healthcare ( GEHC ) will pay Lantheus ( LNTH ) an upfront license fee,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved